Colli-Pee approved by Mexican Health Authority

Novosanis, an innovative developer and producer of medical devices, announced today that Colli-Pee, a user-friendly self-sampling device suited for standardized collection of first-void or first-catch urine has been approved by COFEPRIS, the Federal Commission for the Protection against Sanitary Risk in Mexico.

First-void urine (first 20ml of the urine flow) allows for improved detection of infectious diseases as well as early stage cancers. After gaining regulatory approval in Chile and Brazil earlier this year, Mexico is the third Latin American country where Colli-Pee has been accepted to enter the medical market.

Our Sales and Business Development Director for LATAM, Jeane Brunmark, will be working closely together with our local Mexican distributor Distribuidora Química y Hospitalaria GAP to drive adoption of the Colli-Pee device. The device is currently being launched during the XXXVI National Congress of Oncology which is taking place from November 7 to 10 in Jalisco, Mexico.

“This is yet another big milestone for our company and our team,” says Vanessa Vankerckhoven, CEO of Novosanis. “Mexico, together with Brazil is the biggest market for Medical Devices in Latin-America and we are delighted to further expand our presence globally and improving the accuracy of non-invasive urine-based diagnostics for infectious diseases and oncology,” she continues.